Anouk Verhoeven

Anouk Verhoeven

Auto-generated profile, based on publicly available information

Anouk Verhoeven

Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Toxicology
Verified
Journal Article
Open access
AVAnouk Verhoeven
Anouk Verhoeven
AGAlexandra Gatzios
Alexandra Gatzios
RRRobim M. Rodrigues
Robim M. Rodrigues
JSJulen Sanz-Serrano
Julen Sanz-Serrano
Joery De KockJoery De Kock
Joery De Kock
TVTamara Vanhaecke
Tamara Vanhaecke
Fatty liver disease, which can result from various factors including chemical exposure, is an increasing clinical concern. A key event in its development is steatosis, referring to the accumulation of lipids within hepatocytes. To enable early detection of chemical-induced liver steatosis, we developed a mechanistically-anchored, human-relevant new approach methodology (NAM). This NAM consists of a 2-tiered in vitro test battery, aligned with the adverse outcome pathway (AOP) network for steatosis, and utilizes human skin-derived precursor cells differentiated into hepatic cells (hSKP-HPC), previously shown to be responsive to steatogenic triggers. In total, 6 well-known steatogenic compounds, including 3 pharmaceuticals (sodium valproate, tetracycline hydrochloride, amiodarone hydrochloride), a pesticide (cyproconazole), and 2 plasticizers (tricresyl phosphate and perfluorohexanesulfonic acid) alongside 2 non-steatogenic chemicals (minocycline hydrochloride and tartaric acid), were tested over a 72-hour period. Tier 1 evaluated transcriptional changes in key lipid metabolism pathways, and modulations were observed in nuclear receptors (peroxisome proliferator-activated receptor), fatty acid uptake (fatty acid translocase), de novo lipogenesis (diacylglycerol acyl transferase 2, fatty acid synthase and stearoyl-CoA desaturase 1), as well as in VLDL secretion (apolipoprotein B100). Tier 2 assays assessed and confirmed downstream functional disruptions in fatty acid uptake and lipid accumulation as ultimate specific key events for steatogenic chemicals. Overall, this human stem cell-based NAM offers a promising tool for supporting early hazard identification of steatogenic chemicals across diverse sectors, bridging mechanistic insights to outcomes relevant to the initiation of fatty liver disease.

10 December 2025 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
AVAnouk Verhoeven
Anouk Verhoeven
JSJulen Sanz-Serrano
Julen Sanz-Serrano
Mathieu VinkenMathieu Vinken
Mathieu Vinken

14 May 2024 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
MMMilos Mihajlovic
Milos Mihajlovic
SBSybren De Boever
Sybren De Boever
ATAndrés Tabernila
Andrés Tabernila
ECEllen Callewaert
Ellen Callewaert
JSJulen Sanz-Serrano
Julen Sanz-Serrano
Mathieu VinkenMathieu Vinken
Mathieu Vinken
Parenteral nutrition (PN) is typically administered to individuals with gastrointestinal dysfunction, a contraindication for enteral feeding, and a need for nutritional therapy. When PN is the only energy source in patients, it is defined as total parenteral nutrition (TPN). TPN is a life-saving approach for different patient populations, both in infants and adults. However, despite numerous benefits, TPN can cause adverse effects, including metabolic disorders and liver injury. TPN-associated liver injury, known as intestinal failure-associated liver disease (IFALD), represents a significant problem affecting up to 90% of individuals receiving TPN. IFALD pathogenesis is complex, depending on the TPN components as well as on the patient’s medical conditions. Despite numerous animal studies and clinical observations, the molecular mechanisms driving IFALD remain largely unknown. The present study was set up to elucidate the mechanisms underlying IFALD. For this purpose, human liver spheroid co-cultures were treated with a TPN mixture, followed by RNA sequencing analysis. Subsequently, following exposure to TPN and its single nutritional components, several key events of liver injury, including mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, apoptosis, and lipid accumulation (steatosis), were studied using various techniques. It was found that prolonged exposure to TPN substantially changes the transcriptome profile of liver spheroids and affects multiple metabolic and signaling pathways contributing to liver injury. Moreover, TPN and its main components, especially lipid emulsion, induce changes in all key events measured and trigger steatosis.

15 August 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Marta Moreno-TorresMarta Moreno-Torres
Marta Moreno-Torres
ELErnesto López-Pascual
Ernesto López-Pascual
EMErika Moro
Erika Moro
ARAnna Rapisarda
Anna Rapisarda
BLBirgitte Lindeman
Birgitte Lindeman
Ramiro Jover AtienzaRamiro Jover Atienza
Ramiro Jover Atienza
Drug-induced liver injury (DILI) is a rare but serious adverse drug reaction with a wide range of clinical presentations. While three major DILI phenotypes-hepatocellular, cholestatic, and mixed-are well established, other injury patterns such as steatosis-associated DILI (DIS) are harder to identify and remain underexplored. Existing limited evidence suggests that steatosis is frequent among DILI patients, yet this subtype and its causative drugs have not been systematically characterized in large patient cohorts. This study aims to fill this knowledge gap by collecting information from DIS case reports through AI-supported literature review and data extraction. It also seeks to uncover clinical variables linked to poor outcomes and recovery, and to underscore higher-risk drugs and their distinctive chemical features. A comprehensive literature search on DIS was conducted using keywords and Boolean operators in seven databases. Relevant studies were screened using Sysrev, an AI-supported application for article review and data extraction. Clinical, biochemical, and histopathological data were collected, and drug properties were obtained from databases or by QSAR modeling. The resulting database was subjected to statistical and multivariate analyses, including logistic regression. Data from 251 DIS cases associated with 34 drugs were collected. DIS patients clustered into three subphenotypes with different predominant outcomes: recovery, chronicity, or fatality. Chronic cases showed fibrosis and steatohepatitis with macrosteatosis, while fatal cases often involved microsteatosis and lactic acidosis. Drugs like Didanosine, Zidovudine, Valproate, and Tetracycline were linked to fatal outcome. A predictive model using clinical and chemical features allowed to identify high-concern drugs and hazardous chemical attributes.

21 May 2026 in Chemico-Biological Interactions
Verified
Journal Article
Open access
AVAnouk Verhoeven
Anouk Verhoeven
DGDomenico Gadaleta
Domenico Gadaleta
NINisreen H.K. Isbaita
Nisreen H.K. Isbaita
JJJian Jiang
Jian Jiang
JSJulen Sanz-Serrano
Julen Sanz-Serrano
Mathieu VinkenMathieu Vinken
Mathieu Vinken
Fatty liver disease is the most prevalent hepatic pathology, with accumulating evidence suggesting that chemical exposure may contribute to its development and progression. Consequently, mechanistic understanding of perturbations leading to liver steatosis is essential for chemical safety assessment. This study introduces a new approach methodology (NAM), mechanistically anchored in an adverse outcome pathway network, which integrates in silico and in vitro approaches to enable early detection of steatogenic chemicals upon repeated dose exposure. For this purpose, 7 reference steatogenic chemicals, including 3 pharmaceuticals (sodium valproate, tetracycline hydrochloride and amiodarone hydrochloride), a pesticide (cyproconazole), and 3 plasticizers (tricresyl phosphate, perfluorohexanesulfonic acid and perfluorooctanoic acid) as well as 2 non-steatogenic chemicals (minocycline hydrochloride and tartaric acid) were evaluated at 3 concentrations to induce molecular initiating events and key events related to liver steatosis. Modulations in ligand-activated transcription factors were assessed using an in silico tiered workflow combining (Q)SAR, read-across and docking. Human HepaRG liver cells were subsequently used to quantify transcriptional and functional changes in downstream key events, including lipid accumulation, fatty acid uptake, mitochondrial β-oxidation, lipid secretion, mitochondrial dysfunction, endoplasmic reticulum stress and oxidative stress. A steatogenic score was calculated for each chemical by integrating the biological relevance and the magnitude of responses across all assessed endpoints. These scores clearly distinguished steatogenic from non-steatogenic chemicals. Overall, the current study shows the potential of the NAM to identify the steatogenic properties of chemicals during early stages of hazard assessment.

12 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMarie Corradi
Marie Corradi
IDIvo Djidrovski
Ivo Djidrovski
LLLuiz Carlos Maia Ladeira
Luiz Carlos Maia Ladeira
BSBernard Staumont
Bernard Staumont
AVAnouk Verhoeven
Anouk Verhoeven
MOMarek Ostaszewski
Marek Ostaszewski
As biomedical knowledge keeps growing, resources storing available information multiply and grow in size and complexity. Such resources can be in the format of molecular interaction maps, which represent cellular and molecular processes under normal or pathological conditions. However, these maps can be complex and hard to navigate, especially to novice users. Large Language Models (LLMs), particularly in the form of agentic frameworks, have emerged as a promising technology to support this exploration. In this article, we describe a user-driven process of prototyping, development, and user testing of Llemy, an LLM-based system for exploring these molecular interaction maps. By involving domain experts from the very first prototyping in the form of a hackathon and collecting both fine-grained and general feedback on more refined versions, we were able to evaluate the perceived utility and quality of the developed system, in particular for summarising maps and pathways, as well as prioritise the development of future features. We recommend continued user-driven development and benchmarking to keep the community engaged. This will also facilitate the transition towards open-weight LLMs to support the needs of the open research environment in an ever-changing technology landscape.